Research programme: monoclonal antibody biosimilars - NeuClone/Serum Institute of India

Drug Profile

Research programme: monoclonal antibody biosimilars - NeuClone/Serum Institute of India

Latest Information Update: 22 Mar 2016

Price : $50

At a glance

  • Originator NeuClone; Serum Institute of India
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase Unknown Cancer; Inflammation

Most Recent Events

  • 22 Mar 2016 Research programme: monoclonal antibody biosimilars - NeuClone/Serum Institute of India is available for licensing in Australia, Canada, Europe, Japan, New Zealand, Scandinavia, South Korea, Taiwan, USA, United Kingdom as of 22 Mar 2016. http://www.neuclone.com
  • 22 Mar 2016 Investigation in Cancer in India, Australia (Parenteral)
  • 22 Mar 2016 Investigation in Inflammation in India, Australia (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top